GR-1802

Severe Asthma Pipeline Shows Promise with Over 50 Therapies in Development

7 months ago

• DelveInsight reports a robust severe asthma pipeline with over 50 therapies in development by more than 40 companies, targeting unmet needs in this challenging condition. • Key players like GSK, Sanofi, and AstraZeneca are advancing novel drugs, including biologics and small molecules, through various clinical trial phases for severe asthma. • Recent data presentations highlight potential new treatments, such as Kinaset's frevecitinib (KN-002) and Sanofi's rilzabrutinib, showing promise in improving outcomes for severe asthma patients. • The pipeline includes diverse mechanisms of action, such as cytokine modulators and IgE inhibitors, reflecting a growing understanding of asthma's complexity and personalized treatment approaches.

Severe Asthma Pipeline Shows Promise with Over 50 Therapies in Development

Drug Development Updates